Federal Autism Briefing Linked To Shifts In Acetaminophen And Leucovorin Requests

Research: Tylenol orders dropped and a little-known drug surged after a White House autism announcement

Acetaminophen, the active ingredient in Tylenol, has been a trusted pain reliever for pregnant women for generations. Doctors have long considered it one of the safest pain and fever medications available during pregnancy. On September 22, 2025, that decades-old medical consensus collided with a White House briefing, and lost, at least for a time.

At that briefing, President Donald Trump and FDA Commissioner Dr. Marty Makary warned the public away from acetaminophen during pregnancy, claiming research linked it to autism spectrum disorder in children. No new clinical data were introduced.

In the same session, officials promoted leucovorin, a prescription drug approved for a rare metabolic condition, as “an exciting therapy that may benefit large numbers of children who have suffered from autism.” Within weeks, prescribing patterns shifted measurably.

According to research published in The Lancet, emergency room acetaminophen orders among pregnant patients dropped 10%. Leucovorin prescriptions for children surged 71%. Both shifts appeared within the first two weeks after the briefing.

What the Science Shows About Acetaminophen in Pregnancy

Research cited at the briefing to support the acetaminophen-autism claim came from a contested body of literature. A systematic review and meta-analysis published in January 2026 in The Lancet, examining the full body of evidence on the question, found no increased rates of autism, ADHD, or intellectual disability among children born to mothers who used acetaminophen during pregnancy.

When pregnant women stop taking acetaminophen, they do not simply stop taking medication. They either go without pain relief or reach for something less safe. Untreated fever during pregnancy is a documented risk factor for neurological disorders in offspring, a concern the study’s authors flagged directly. Steering pregnant patients away from a medication widely considered safe during pregnancy, based on disputed evidence, carries real medical consequences.

Leucovorin’s promotion rested on similarly thin ground. It has a legitimate use in treating cerebral folate deficiency, a genuinely rare condition, but it was not approved for autism. Following the briefing, the FDA updated leucovorin’s label to note its potential in treating cerebral folate deficiency, stopping well short of an autism-specific indication. Prescribing it outside that narrow context, the authors cautioned, “might confer false expectations and unnecessary side-effects.”

How Researchers Tracked the White House Briefing’s Impact

To measure the fallout, researchers at Harvard Medical School and Brown University School of Public Health analyzed data from Cosmos, an electronic health records database covering more than 294 million patients across over 1,600 hospitals and 37,000 clinics nationwide.

For acetaminophen, the study focused on pregnant women ages 15 to 44 treated in emergency departments. Researchers built a pre-briefing baseline from data running June 30 through September 21, 2025, then projected what prescribing rates would have looked like had the briefing never happened. Post-briefing data ran through December 7. For leucovorin, the team tracked new outpatient prescriptions for children ages 5 to 17, benchmarked against comparison medications including aripiprazole and risperidone, the only two FDA-approved drugs for autism spectrum disorder, and folic acid preparations.

Acetaminophen Orders Fell, Leucovorin Prescriptions Skyrocketed

Among pregnant women in emergency departments, acetaminophen orders fell 10% across the full study period, with the steepest drop, roughly 20%, arriving in week three. Acetaminophen use among non-pregnant women of the same age showed no significant change, pointing squarely at the pregnancy-specific messaging from officials.

Leucovorin prescriptions moved sharply in the opposite direction. New prescriptions for children ages 5 to 17 rose 71% across the full period. During the second week after the briefing alone, prescriptions more than doubled, landing 113% above what models had predicted. Aripiprazole and risperidone, the FDA-approved autism medications, showed smaller increases later in the study period, which researchers suggested may reflect families searching for alternatives after a leucovorin shortage hit the US in November 2025. Folic acid, included as a comparison drug, showed no significant change.

The White House Autism Briefing and a Familiar Pattern

Researchers drew a direct parallel to the COVID-19 pandemic, when statements by officials promoting unproven treatments drove rapid spikes in drug use. At least in that case, some evidence had entered public discourse. Here, measurable change arrived within weeks anyway.

Authors are careful to note the study cannot prove the briefing caused the prescribing shifts, nor can it determine whether changes were driven by patients requesting different treatments or physicians proactively adjusting their practice. What the data show is a timed association between the briefing and shifts that did not appear in comparison drugs.

Acetaminophen use recovered somewhat as the weeks passed, a rebound researchers attribute to countermessaging from medical organizations and the natural fade of a news cycle. Leucovorin remained elevated throughout the study period, consistent with its use as a long-term treatment.

A briefing built on disputed citations coincided with measurable changes in how patients and providers across a large national health network approached pregnancy care and autism treatment. For one of the most thoroughly studied drugs in medicine, that is a telling example of how quickly official messaging can coincide with changes in clinical practice.

---

Disclaimer: This article is based on a research correspondence published in The Lancet and is intended for informational purposes only. It does not constitute medical advice. Pregnant individuals and parents of children with autism spectrum disorder should consult a qualified healthcare provider before making any changes to medications or treatment plans.

---